Antiatherosclerotic effects of ace inhibitors:Where are we now?

American Journal of Cardiovascular Drugs

Volumn 1, Issue 5, 2001, Pages 315-320

  Lonn, Eva ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HGH McMaster Clinic Room 261 ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIOCARDIOGRAPHY; ARTERIOSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ENDOSCOPIC ECHOGRAPHY; HEART INFARCTION; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; CORONARY ANGIOGRAPHY; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0037989571     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101050-00001     Document Type: Article

References (36)

1. Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta 1971; 250: 261-5
2. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-69
3. Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998; 19 Suppl. J: J2-6
4. Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-9
5. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-8
6. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32: 965-71
7. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution of alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23
8. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8
9. Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin- converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-41
10. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67
11. Chobanian AV, Haudenschild CC, Nickerson C, et al. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-1
12. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15 Suppl. 5: S65-72
13. Rolland PH, Charpiot P, Friggi A, et al. Effects of angiotensin- converting enzyme inhibition with perindopril on hemodynamics, arterial structure and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993; 71 Suppl. 17: 22E-7E
14. Powell JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8
15. Hoshida S, Nishida M, Yamashita N, et al. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis 1997; 130: 53-9
16. Alderman MH, Madhavan SH, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104
17. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359; 641-4
18. Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245: 315-7
19. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65
20. Anderson TJ, Elstein E, Haber H, et al. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-6
21. Wilmink H, Banga JD, Hijmering M, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II type I receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 1999; 34: 140-5
22. Vaughan DE, Rouleau JL, Ridker PM. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators. Circulation 1997; 96: 442-7
23. Wright RA, Flapan AD, Alberti KG. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73
24. Cashin-Hemphill L, Holmvang G, Chan RC, et al. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Quinapril Ischemic Event Trial (QUIET). Am J Cardiol 1999; 83: 43-7
25. Teo KK, Burton JR, Buller CE, et al. Long term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748-54
26. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol 1997; 146: 483-94
27. O?Leary DH, Polak JF, Kronmal RA, et al., for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22
28. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease (PART 2 trial). J Am Coll Cardiol 2000; 36: 438-43
29. Lonn E, Yusuf S, Dzavik V, et al., for the SECURE Investigators. Effects of ramipril and of vitamin E on atherosclerosis: results of the prospective randomized Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25
30. Hosomi N, Mizushige K, Ohyama H, et al. ACE inhibition with enalapril slows progressive intima-media thickening of common carotid artery in NIDDM patients [abstract]. Circulation 2000; 102: Suppl: II: II-869
31. Espeland MA, Craven TE, Riley WA, et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thickness. Stroke 1996; 27: 480-5
32. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8
33. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. (SAVE Investigators). Circulation 1994; 90: 1731-8
34. Kober L, Torp-Pedersen C, Carlsen JE, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 333: 1670-6
35. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin- converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53